The 20th Fraunhofer Seminar “Models of Lung Disease” will take place at the CRC Hannover from June 23 to 24, 2022. Different topics of translational research will be addressed in excellent presentations, with a focus on infections of the lung.
more info© AdobeStock
Alternative to animal models – advances in medicine through human-relevant disease models.
more info
Feasibility study of an active-substance-based review system (“monographs”) and other potential alternatives for the environmental risk assessment of veterinary medicinal products.
New development pipeline for RNA-based drugs, aimed at accelerating therapeutic approaches targeting viral diseases.
more info© Karin Kaiser / MHH
With our decades of experience in infection and airway research, drug development, biomedical engineering, and in the field of chemical risk assessment, we are meanwhile involved in numerous projects to fight the COVID-19 pandemic.
more info© Fraunhofer
The High-Performance Center Medical and Pharmaceutical Engineering, launched in March, creates a platform for research and the transfer of innovations into patient care.
more info© Fraunhofer IMTE, Dr. Thomas Friedrich
The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 75 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on cardiopulmonary research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.
With a staff of 394 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.
Fraunhofer Institute for Toxicology and Experimental Medicine